---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-23-000062"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T02:45:16.273481+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics sells Reneo shares for $4.4M to fund cadisegliatin Phase 3

## Summary
- Sold all Reneo common shares held under 2017 license for ~$4.4M gross proceeds.
- Proceeds support preparations for launch of cadisegliatin Phase 3 in type 1 diabetes.
- Remains eligible for up to $94.5M in clinical, regulatory & commercial milestones.
- Eligible for tiered royalties (mid-single to low teens) on potential net sales of mavodelpar.

## SEC filing metadata
- accession: 0001641489-23-000062
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000062/0001641489-23-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000062/vtvt-20231030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-23-000062
- JSON: https://secwatch.observer/filing/0001641489-23-000062.json
- Plain text: https://secwatch.observer/filing/0001641489-23-000062.txt

## Key facts
- Material Agreements
  vTv Therapeutics Inc. entered into Common Stock Repurchase Agreement with Reneo Pharmaceuticals, Inc. valued at approximately $4.4 million (effective 2023-10-30).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Reneo Pharmaceuticals, Inc.
  - Value: approximately $4.4 million
  - Effective: 2023-10-30
  source text: On October 30, 2023, vTv Therapeutics LLC (“vTv LLC”), the principal operating subsidiary of vTv Therapeutics, Inc. (the “Company”) entered into a Common Stock Repurchase Agreement (the "Repurchase Agreement") with Reneo Pharmaceuticals, Inc. (“Reneo”) pursuant to which Reneo agreed to purchase all shares of common stock of Reneo that had been owned by vTv LLC. Pursuant to the Repurchase Agreement, Reneo agreed to pay vTv LLC gross proceeds of approximately $4.4 million for the Reneo common stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000062/0001641489-23-000062-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.